A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 389; no. 1; pp. 22 - 32
Main Authors: Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 06.07.2023
Subjects:
Alanine transaminase
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Antiviral drugs
Arthralgia
Asthenia
Biopsy
Cirrhosis
Coinfection - drug therapy
Coinfection - virology
Disease
Eosinophilia
FDA approval
Gastroenterology
Gastroenterology General
Hepatitis B
Hepatitis B surface antigen
Hepatitis B Surface Antigens
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis D, Chronic - drug therapy
Hepatitis delta virus
Hepatitis Delta Virus - genetics
Hepatocytes
Humans
Infections
Infectious Disease
Infectious Disease General
Interferon
Liver cirrhosis
Liver Disease
Liver diseases
Pruritus
Ribonucleic acid
RNA
Viral Infections
Russia
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2213429